Event Coverage

Emilie Aschenbrenner, PharmD, BCOP, highlights how measurable residual disease (MRD) testing can support value-based care in multiple myeloma by guiding personalized treatment intensity, potentially reducing costs and improving outcomes.

Jason Bergsbaken, PharmD, MBA, BCOP, explains the value of pharmacist involvement in precision molecular tumor boards and end-of-life care discussions, highlighting their role in ensuring evidence-based therapy selection, patient-specific recommendations, and shared decision-making that aligns treatment with individual goals.

Clayton Irvine, PharmD, MBA, MS, discusses strategies to address payer-driven biosimilar and prior authorization challenges through integrated digital solutions, while advocating for flexible, regularly reviewed treatment pathways supported by molecular tumor boards and artificial intelligence to balance standardization with personalized, biomarker-driven oncology care.

Clayton Irvine, PharmD, MBA, MS, explains that leveraging high-quality, real-world data; cross-institutional collaboration; standardized care pathways; advanced technologies; and integrated academic–community oncology partnerships can improve treatment decision-making, reduce financial toxicity, address drug shortages, and optimize infusion center efficiency.

Jason Bergsbaken, PharmD, MBA, BCOP, highlights the operational challenges of value-based oncology care while emphasizing the need to balance standardized treatment pathways with flexibility for personalized, biomarker-driven care.

Jason Bergsbaken, PharmD, MBA, BCOP, highlights the growing role of real-world data in validating or de-implementing therapies, the need for vigilant postapproval outcomes monitoring, and the value of academic–community oncology partnerships.

Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies are transforming multiple myeloma care, with earlier use, expanded community access, and outpatient delivery models offering opportunities to improve value, safety, and equity in treatment.

On April 10, 2025, leaders from Louisiana health systems convened in New Orleans to provide updates on the Healthy State initiative to improve population health in the state.

Discussions at a recent Institute for Value-Based Medicine® event highlighted the interconnected nature of cardio-kidney-metabolic disease and emphasized the need for integrated, patient-centered care.

Cardiologists, primary care physicians, and value-based care leaders convened in Phoenix, Arizona, on November 12, 2024, to share case studies and insights on how to align cardiology with the principles of value-based care, including through the application of digital tools.

Tiffany Meng, PharmD, an oncology pharmacist, UCSF Health, shares how pharmacists can collaborate with physicians to find the most effective and affordable therapies for patients.

Experts at a recent Institute for Value-Based Medicine event emphasized the importance of early intervention, policy innovation, and proactive collaboration to transform the management of kidney disease and optimize patient outcomes.

Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.

At an Institute for Value-Based Medicine® event held in Aurora, Colorado, experts discussed strategies to improve patient outcomes and manage health care costs in neurological diseases.

An IVBM event cohosted by The American Journal of Managed Care focused on Healthy State, a multiyear, multistakeholder commitment to moving Louisiana ahead in America’s Health Rankings.

Clinicians, researchers, and payer experts convened in Aurora, Colorado, on August 13, 2024, for discussions on ensuring that the recent advancements in lipid management are making their way to patients.

At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care®, experts discussed efforts to implement obesity management science into practice.

At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care® and Sutter Health, experts illuminated the current state of cardiometabolic health care and offered a glimpse into the future.

The number of Americans with type 2 diabetes and/or obesity is rising, and the entry of therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists has been revolutionary.

At an Institute for Value-Based Medicine® event cohosted by The American Journal of Managed Care® and Optum, speakers emphasized that innovation is urgently needed in primary care delivery to address the broken US health care system.

At an Institute for Value-Based Medicine® event held in Phoenix, Arizona, experts from Banner Health and Aetna discussed how health inequities and social determinants of health can affect primary care in patients with any type of insurance.

Pharmacy stakeholders met in Newport Beach, California, for an Institute for Value-Based Medicine® event to discuss the intersection of value-based medicine and pharmacy.

Health care providers and policy experts gathered in New Orleans, Louisiana, to discuss the complex interplay between food insecurity and obesity as well as the expanding toolbox of options to support patients in achieving a healthy weight.

Diagnosing and treating gestational diabetes can have long-term positive effects on the health of the mother and the baby, warranting a distinct focus on the condition, according to an Institute for Value-Based Medicine® event held in Cleveland, Ohio.

Clinicians and leaders from Duke University convened in Durham, North Carolina, to discuss unmet needs in the care of patients with diabetes and opportunities to close those gaps through coordination, education, support, and technology.